Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.
about
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Therapeutic efficacy of SYM004 ...... cetuximab and MET activation.
@en
Therapeutic efficacy of SYM004 ...... cetuximab and MET activation.
@nl
type
label
Therapeutic efficacy of SYM004 ...... cetuximab and MET activation.
@en
Therapeutic efficacy of SYM004 ...... cetuximab and MET activation.
@nl
prefLabel
Therapeutic efficacy of SYM004 ...... cetuximab and MET activation.
@en
Therapeutic efficacy of SYM004 ...... cetuximab and MET activation.
@nl
P2093
P2860
P356
P1433
P1476
Therapeutic efficacy of SYM004 ...... cetuximab and MET activation.
@en
P2093
Alessia Parascandolo
Davide Ciardiello
Erika Martinelli
Floriana Morgillo
Giulia Martini
Mikko O Laukkanen
Stefania Napolitano
Teresa Troiani
Valentina Belli
Vincenzo Sforza
P2860
P304
67592-67604
P356
10.18632/ONCOTARGET.18749
P407
P577
2017-06-27T00:00:00Z